A meta-analysis of venous thromboembolic events associated with VEGFR-TKIs found that the use of VEGFR-TKIs does not significantly increase the risk of VTEs, the risk of VTEs in cancer patients is mainly affected by tumor types, host factors, and concomitant usage of anticancer drugs47. This evidence concerns the gene KDR and neoplasm.